Paclitaxel in pretreated metastatic penile cancer: Final results of a phase 2 study

European Urology

Volumn 60, Issue 6, 2011, Pages 1280-1284

  Di Lorenzo, Giuseppe ^a   Federico, Piera ^a   Buonerba, Carlo ^a   Longo, Nicola ^a   Carten, Giacomo ^b   Autorino, Riccardo ^c   Perdon, Sisto ^d   Ferro, Matteo ^a   Rescigno, Pasquale ^a   D'Aniello, Carmine ^a   Matano, Elide ^a   Altieri, Vincenzo ^a   Palmieri, Giovannella ^a   Imbimbo, Ciro ^a   De Placido, Sabino ^a   Mirone, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Activity and toxicity; Metastatic penile cancer; Paclitaxel

Indexed keywords

BLEOMYCIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PENIS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; HUMANS; ITALY; MALE; MIDDLE AGED; PACLITAXEL; PENILE NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80255131127     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.08.028     Document Type: Article

References (20)

1. G. Pizzocaro, F. Algaba, and S. Horenblas EAU penile cancer guidelines 2009 Eur Urol 57 2010 1002 1012
2. F. Dexeus, C. Logothetis, and A. Sella Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract J Urol 146 1991 1284 1287
3. G.P. Haas, B.A. Blumenstein, and R.G. Gagliano Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group Study J Urol 161 1999 1823 1825 (Pubitemid 29420741)
4. A.M. Hussein, P. Benedetto, and K.S. Sridhar Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas Cancer 65 1990 433 438
5. D.G. Power, D.J. Galvin, and S. Cuffe Cisplatin and gemcitabine in the management of metastatic penile cancer Urol Oncol 27 2009 187 190
6. C. Theodore, I. Skoneczna, and I. Bodrogi A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992) Ann Oncol 19 2008 1304 1307 (Pubitemid 351911962)
7. P.G. Morris, and C.A. Hudis Optimizing dose-dense regimens for early-stage breast cancer Nat Rev Clin Oncol 7 2010 678 679
8. J. Gines, E. Sabater, and C. Martorell Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomized clinical trials Clin Transl Oncol 13 2011 485 498
9. S.M. Gadgeel The optimal chemotherapy for stage III non-small cell lung cancer patients Curr Oncol Rep 13 2011 272 279
10. C. Bermejo, E. Busby, and P.E. Spiess Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma J Urol 177 2007 1335 1338 (Pubitemid 46435966)
11. G. Pizzocaro, N. Nicolai, and A. Milani Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results Eur Urol 55 2009 546 551
12. G. Di Lorenzo, G. Carten, and R. Autorino Activity of paclitaxel in pretreated metastatic penile cancer patients Anticancer Drugs 20 2009 277 280
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. National Cancer Institute. Cancer therapy evaluation program (CTEP) Web site. Common toxicity criteria for adverse events, v3.0, 2003. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm.
15. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10 (Pubitemid 19099520)
16. E.L. Kaplan, and P. Meier Non-parametric estimation for incomplete observation J Am Stat Assoc 53 1958 457 481
17. C. Buonerba, P. Federico, and C. D'Aniello Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients Cancer Chemother Pharmacol 67 2011 1455 1461
18. O.W. Hakenberg, J.B. Nippgen, and M. Froehner Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma BJU Int 98 2006 1225 1227 (Pubitemid 44721230)
19. R. Salvioni, N. Nicolai, and L. Piva Pilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advanced squamous cell carcinoma (SCC) of the penis [abstract 4639]. American Society of Clinical Oncology, 2011 annual meeting proceedings J Clin Oncol 29 Suppl 2011
20. L.C. Pagliaro, D.L. Williams, and D. Daliani Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study J Clin Oncol 28 2010 3851 3857